Product Information
EMGALITY 300 MG DOSE (100 MG/ML X 3 SYRINGES) is a brand product labeled by Eli Lilly and Company, priced at $612.9103 per ML under NDC 00002311509. Its NADAC has been published 336 times since Jan 22, 2020.
Strength
100 mg/mL
Manufacturer
Eli Lilly and CompanyNDC
00002311509
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Last Updated
6/17/2026
Active Ingredients
GALCANEZUMABApproval Type
Biologic (BLA)
FDA Application
BLA761063On Market Since
6/4/2019
Price Statistics
The NADAC for EMGALITY 300 MG DOSE (100 MG/ML X 3 SYRINGES) has been published 336 times since Jan 22, 2020, and over the history we have for it it has risen 33.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $612.9103 per ML |
|---|---|
| All-time high | $612.9103 (Jun 24, 2026) |
| All-time low | $461.0067 (Jan 22, 2020) |
| 52-week high | $612.9103 |
| 52-week low | $594.2803 |
| Median price | $545.9158 |
| Average price | $542.5400 |
| Largest weekly change | +5.0% (Jan 8, 2025) |
| Weeks tracked | 336 |
| Tracking since | Jan 22, 2020 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient, strength, and dosage form. Compare the broader picture on the galcanezumab-gnlm market page.
Lowest-Cost Alternatives
No alternatives available
Frequently asked questions
What is the NADAC price of EMGALITY 300 MG DOSE (100 MG/ML X 3 SYRINGES)?
The current National Average Drug Acquisition Cost (NADAC) for EMGALITY 300 MG DOSE (100 MG/ML X 3 SYRINGES), manufactured by Eli Lilly and Company, is $612.9103 per ML (NDC 00002311509), effective Jun 24, 2026.
How has the price of EMGALITY 300 MG DOSE (100 MG/ML X 3 SYRINGES) changed over time?
Over the history we have for it, the NADAC for EMGALITY 300 MG DOSE (100 MG/ML X 3 SYRINGES) has risen 33.0%. It has been tracked across 336 weekly CMS publications since Jan 22, 2020.
What are the highest and lowest recorded NADAC prices for EMGALITY 300 MG DOSE (100 MG/ML X 3 SYRINGES)?
Since Jan 22, 2020, the NADAC for EMGALITY 300 MG DOSE (100 MG/ML X 3 SYRINGES) has ranged from a low of $461.0067 (Jan 22, 2020) to a high of $612.9103 (Jun 24, 2026), with a median of $545.9158 per ML.
Are there cheaper alternatives to EMGALITY 300 MG DOSE (100 MG/ML X 3 SYRINGES)?
No other NADAC-published product currently shares the active ingredient, strength, and dosage form of EMGALITY 300 MG DOSE (100 MG/ML X 3 SYRINGES), so no direct lower-cost alternative is listed.
Who manufactures EMGALITY 300 MG DOSE (100 MG/ML X 3 SYRINGES)?
EMGALITY 300 MG DOSE (100 MG/ML X 3 SYRINGES) (NDC 00002311509) is labeled by Eli Lilly and Company, and CMS classifies it as a brand product.
Related Drugs
Same classification